NasdaqGS - Nasdaq Real Time Price • USD
Alnylam Pharmaceuticals, Inc. (ALNY)
As of 11:08 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 21 | 21 | 22 | 21 |
| Avg. Estimate | -1.18 | -1.04 | -4.11 | -1.76 |
| Low Estimate | -1.56 | -1.53 | -5.9 | -4.32 |
| High Estimate | -0.27 | -0.09 | -0.96 | 1.36 |
| Year Ago EPS | -1.4 | -2.21 | -3.52 | -4.11 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 21 | 20 | 26 | 23 |
| Avg. Estimate | 427.34M | 464.05M | 1.85B | 2.33B |
| Low Estimate | 405.65M | 435.5M | 1.78B | 1.88B |
| High Estimate | 452.3M | 565.06M | 2.04B | 2.97B |
| Year Ago Sales | 319.29M | 318.75M | 1.83B | 1.85B |
| Sales Growth (year/est) | 33.80% | 45.60% | 1.30% | 25.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.76 | -1.37 | -1.34 | -1.32 |
| EPS Actual | -1.4 | -2.21 | 1.15 | -1.1 |
| Difference | 0.36 | -0.84 | 2.49 | 0.22 |
| Surprise % | 20.50% | -61.30% | 185.80% | 16.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.18 | -1.04 | -4.11 | -1.76 |
| 7 Days Ago | -1.18 | -1.04 | -4.11 | -1.76 |
| 30 Days Ago | -1.18 | -1.04 | -4.18 | -1.76 |
| 60 Days Ago | -1.17 | -1.02 | -4.14 | -1.85 |
| 90 Days Ago | -1.3 | -1.19 | -4.21 | -1.01 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 1 | -- | -- |
Growth Estimates
| CURRENCY IN USD | ALNY | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 15.70% | -- | -- | 1.50% |
| Next Qtr. | 52.90% | -- | -- | 11.40% |
| Current Year | -16.80% | -- | -- | 5.20% |
| Next Year | 57.20% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -177.50% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | BMO Capital: Outperform to Outperform | 3/27/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/5/2024 |
| Maintains | Cantor Fitzgerald: Neutral to Neutral | 2/23/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 2/21/2024 |
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 2/20/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 2/20/2024 |
Related Tickers
IONS Ionis Pharmaceuticals, Inc.
42.00
-1.06%
ARWR Arrowhead Pharmaceuticals, Inc.
21.91
-5.93%
ARGX argenx SE
373.25
-0.47%
INCY Incyte Corporation
50.58
-2.25%
BGNE BeiGene, Ltd.
149.33
+3.62%
BPMC Blueprint Medicines Corporation
89.76
-2.71%
BBIO BridgeBio Pharma, Inc.
23.87
-4.63%
AGIO Agios Pharmaceuticals, Inc.
31.60
-0.22%
APLS Apellis Pharmaceuticals, Inc.
47.59
-4.69%
CYTK Cytokinetics, Incorporated
65.19
-2.45%